Moderna Inc
NASDAQ:MRNA

Watchlist Manager
Moderna Inc Logo
Moderna Inc
NASDAQ:MRNA
Watchlist
Price: 30.41 USD -2.38% Market Closed
Market Cap: 11.9B USD

Intrinsic Value

The intrinsic value of one MRNA stock under the Base Case scenario is 24.57 USD. Compared to the current market price of 30.41 USD, Moderna Inc is Overvalued by 19%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MRNA Intrinsic Value
24.57 USD
Overvaluation 19%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Moderna Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about MRNA?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is MRNA valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Moderna Inc.

Explain Valuation
Compare MRNA to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Moderna’s revenue remains heavily reliant on its COVID-19 vaccine, and diminished global demand for boosters, along with heightened competition from alternative formulations, could significantly erode sales and margins.

Clinical trial outcomes for non–COVID-19 mRNA therapeutic candidates are still unproven, posing a risk that setbacks in other pipeline products could undermine investor confidence and hamper long-term growth prospects.

Rapidly evolving regulatory environments and potential scrutiny over mRNA’s long-term safety profile may hinder approvals or market adoption, especially if adverse events emerge for newer, less-tested indications.

Bull Theses

The mRNA platform’s modular nature and rapid development cycle positions Moderna to quickly expand its pipeline beyond COVID-19, enabling potential breakthroughs in vaccines for influenza, RSV, cancer, and rare diseases.

Substantial cash reserves from COVID-19 vaccine sales provide a strong financial foundation for aggressive R&D efforts and flexible strategic partnerships, giving Moderna a distinct edge over less-capitalized biotech peers.

Collaborations with global pharmaceutical giants and a growing network of research alliances boost Moderna’s research capabilities and commercial reach, supporting the company’s ambition to diversify revenue streams through multiple mRNA-based products.

Show More Less
How do you feel about MRNA?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Moderna Inc

Current Assets 6.6B
Cash & Short-Term Investments 4.5B
Receivables 1.2B
Other Current Assets 935m
Non-Current Assets 5.5B
Long-Term Investments 2.2B
PP&E 2.9B
Intangibles 99m
Other Non-Current Assets 422m
Current Liabilities 1.7B
Accounts Payable 267m
Accrued Liabilities 1.2B
Other Current Liabilities 219m
Non-Current Liabilities 1.1B
Long-Term Debt 26m
Other Non-Current Liabilities 1.1B
Efficiency

Free Cash Flow Analysis
Moderna Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Moderna Inc

Revenue
2.2B USD
Cost of Revenue
-815m USD
Gross Profit
1.4B USD
Operating Expenses
-4.5B USD
Operating Income
-3.1B USD
Other Expenses
7m USD
Net Income
-3.1B USD
Fundamental Scores

MRNA Profitability Score
Profitability Due Diligence

Moderna Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Strong 3Y Average Gross Margin
Declining Gross Margin
Declining Net Margin
19/100
Profitability
Score

Moderna Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

MRNA Solvency Score
Solvency Due Diligence

Moderna Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Negative Net Debt
Low D/E
Short-Term Solvency
65/100
Solvency
Score

Moderna Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MRNA Price Targets Summary
Moderna Inc

Wall Street analysts forecast MRNA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MRNA is 37.59 USD with a low forecast of 17.17 USD and a high forecast of 141.75 USD.

Lowest
Price Target
17.17 USD
44% Downside
Average
Price Target
37.59 USD
24% Upside
Highest
Price Target
141.75 USD
366% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Moderna Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for MRNA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

MRNA Insider Trading
Buy and sell transactions by insiders

MRNA News

Other Videos
What is the Intrinsic Value of one MRNA stock?

The intrinsic value of one MRNA stock under the Base Case scenario is 24.57 USD.

Is MRNA stock undervalued or overvalued?

Compared to the current market price of 30.41 USD, Moderna Inc is Overvalued by 19%.

Back to Top